Our first drug candidate will be a topical formulation of cerium oxide nanoparticles for prevention of radiation dermatitis caused by radiotherapy. 


According to the American Cancer Society, the United States is projected to have over 250,000 new cases of invasive breast cancer and approximately 40,000 deaths from breast cancer in 2017. 


We plan to target patients who are receiving radiotherapy following breast-conserving surgery for early stage breast cancer. 


  • 170,000 Breast Cancer patients in the United States receive potentially life saving radiotherapy following breast-conserving surgery2,3
  • More than 90% of these patients are injured to some extent by the radiation therapy4
  • 100% of these patients are potentially treatable with a topical product


1“How Common is Breast Cancer?.” American Cancer Society, 24 May 2016. Web. 15 Aug 2017

2“Breast Cancer Treatment.” Radiology for Patients, 24 May 2016. Web. 15 Aug 2017

3Kummerow, Kristy et al. “Nationwide trends in mastectomy for early-stage breast cancer.” JAMA Surg. 150 (2015): 9-16

4Bray Fleta, et al. “Acute and Chronic Cutaneous Reactions to Ionizing Radiation Therapy.” Dermatol Ther. 6 (2016): 185-206 




Print Print | Sitemap
© Biocurity